Enhua Pharmaceutical (002262.SZ): Class 1 innovative drug NH302 injection has been approved to commence clinical trials.

Zhito Finance APP reported that Enhua Pharmaceutical (002262.SZ) has announced that the company recently received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Class 1 chemical drug NH302 injection, and will soon commence clinical trials. NH302 is a peripheral selective Kappa receptor agonist. Preclinical trial results indicate that NH302 exhibits strong agonistic activity on Kappa receptors and demonstrates good analgesic effects in various pain animal models, with a low effective dose, prolonged duration of action, and a wide safety window, showing promise for development as a treatment for acute pain with significant clinical advantages.